Prescribing guide
Uplizna (inebilizumab-cdon)Pre-infusion screening, premedication, dosing and prior authorization criteria for generalized myasthenia gravisFor prescribers and their offices treating generalized myasthenia gravis: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS. HBV, quantitative immunoglobulin and TB screening before dose 1, immunizations at least 4 weeks before, prior authorization, a site of care, and no active infection on each dose day.
Example PA threshold
FEP example: age 18 or older, AChR or MuSK antibody positive, MGFA class II to IV, baseline MG-ADL or QMG score, 1 prior agent, no active HBV, no active or untreated latent TB.
Monitoring
Premedicate every infusion; observe during and 1 hour after; infection check before each dose; immunoglobulins at baseline, during treatment and until B-cell repletion; HBV monitoring for at-risk patients.
Support line
Amgen By Your Side, Patient Access Liaison 1-833-842-8477; as little as $0 for drug and infusion costs on eligible commercial plans; no administration support for MA or RI residents.
Give your patient their plan
A one-page handout for starting Uplizna, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/uplizna-myastheniaBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Enroll in Amgen By Your Side | Patient calls 1-833-842-8477, or the office starts enrollment on AmgenByYourSide.com and submits it with patient consent. A Patient Access Liaison is assigned. | Amgen By Your Side FAQ |
| Benefits investigation | After the patient signs a HIPAA release, the team reviews coverage and estimated out-of-pocket costs. It also checks whether PA is required and whether a medical exception with a letter of medical necessity is needed. | Amgen insurance page |
| Complete pre-dose screening | HBsAg and anti-HBV tests, quantitative serum immunoglobulins, TB risk evaluation and latent TB testing. Consider anti-TB therapy first for inadequately treated latent TB or risk factors with a negative test; consult infectious disease. | FDA label |
| Vaccines | All immunizations per guidelines at least 4 weeks before initiation (section 5.2; section 2.1 ties the window to live or live-attenuated vaccines). Not recommended during treatment or after discontinuation until B-cell repletion. | FDA label |
| Site of care | A Patient Access Liaison can help find an infusion center; Amgen notes home infusion may be an option subject to the physician and the plan. The label requires an experienced healthcare professional with access to support for severe reactions. | Starting Uplizna |
| Product and preparation | One carton of three 100mg/10mL single-dose vials (NDC 75987-150-03) per dose. Use a 21-gauge or smaller bore needle; no vial spikes or closed system transfer devices (added September 2026). Store diluted solution up to 24 hours refrigerated or 4 hours at room temperature before starting. | FDA label |
| Co-pay program | Amgen Commercial Co-Pay Program: commercial insurance with cost share, US residents, as little as $0 for drug and infusion costs. Excludes Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE, state, patient foundation or other pharmaceutical programs. | Amgen financial support |
| Program limits | Eligibility criteria and program maximums apply; no dollar figure is published on the pages read. Residents of Massachusetts or Rhode Island are not eligible for administration support. | Uplizna site |
| Denial path | Medical exception request or appeal through the office; Amgen By Your Side educates on both. Independent foundations listed by Amgen: The Assistance Fund, Good Days, PAN Foundation, NORD. | Amgen insurance page |
Prior authorization criteria and what to document
One public policy as the example: Blue Cross Blue Shield Federal Employee Program, April 1, 2026. Approval twelve months at first, up to 9 vials. Renewals are 12 months at a time, up to 6 vials, when the MG-ADL or QMG total score has dropped at least 2 points from baseline. This policy was approved on March 6, 2026 and cites the December 2025 label. It predates the September 2026 label, which changed only how pharmacists draw the medicine from the vial. The MGFA class, baseline score and earlier-medicine criteria are the plan's own and are not conditions in the label. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | Generalized myasthenia gravis, age 18 or older | Diagnosis in the note | FEP Blue policy |
| Serology | Presence of autoantibodies against AChR or MuSK | Antibody result with date | FEP Blue policy |
| Severity class | MGFA clinical classification class II to IV | Exam and classification in the note | FEP Blue policy |
| Baseline score | One of: MG-ADL total score of 11 or higher, MG-ADL of 6 to 10 with at least 50% attributed to non-ocular items, or QMG total score of 11 or higher | Dated, itemized score sheet | FEP Blue policy |
| Prior therapy | Inadequate response, intolerance or contraindication to one of: acetylcholinesterase inhibitor, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate, cyclophosphamide | Medication history with dates and outcome | FEP Blue policy |
| Hepatitis B | No active hepatitis B infection | HBV screening results | FEP Blue policy |
| Tuberculosis | No active or untreated latent tuberculosis | TB test result and any treatment history | FEP Blue policy |
| Vaccines | Not given concurrently with live vaccines | Vaccine history and plan | FEP Blue policy |
| Contraception | Females of reproductive potential advised on effective contraception during treatment and 6 months after the last dose | Counseling note | FEP Blue policy |
| Renewal | Decrease of MG-ADL or QMG total score from baseline of 2 points or more; first approval 12 months and 9 vials, renewals 12 months and 6 vials | Repeat score against the baseline sheet | FEP Blue policy |
Uplizna dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1 | 300mg IV, titrated to completion over about 90 minutes. | FDA label |
| Day 15 | 300mg IV, 2 weeks after the first infusion. | FDA label |
| Every 6 months | 300mg IV, starting 6 months from the first infusion. | FDA label |
| Infusion rate (250mL bag) | 42mL/hour for minutes 0 to 30, 125mL/hour for minutes 31 to 60, 333mL/hour from minute 61 to completion. Bring the prepared solution to room temperature first. | FDA label |
| Premedication, every infusion | Corticosteroid IV 30 minutes before (methylprednisolone 80 to 125mg or equivalent). Antihistamine (diphenhydramine 25 to 50mg) and antipyretic (acetaminophen 500 to 650mg) orally 30 to 60 minutes before. | FDA label |
| Reaction management | Life-threatening or disabling reaction: stop immediately and permanently, give supportive care. Less severe: pause, slow the rate and/or treat symptoms. | FDA label |
| Pediatric and geriatric | Safety and effectiveness not established in pediatric patients. gMG studies had too few patients 65 and older to assess differences. | FDA label |
| Other indications | AQP4 antibody positive NMOSD and IgG4-RD use the same schedule (section 2.3); not covered on this page. | FDA label |
Monitoring the Uplizna label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Before dose 1 | HBV, quantitative serum immunoglobulins, TB | Contraindicated with active HBV or active or untreated latent TB; hepatology consult for HBsAg-negative HBcAb-positive or HBsAg-positive; immunology consult if immunoglobulins are low | FDA label |
| Each infusion | Infusion reactions, including anaphylaxis: headache, nausea, somnolence, dyspnea, fever, myalgia, rash, palpitations | Observe during and at least 1 hour after. 10.1% in the gMG randomized period; most common with the first infusion | FDA label |
| Before each dose | Active infection | Delay until resolved. gMG randomized period: UTI 7%, nasopharyngitis 7% | FDA label |
| During treatment and after stopping | Quantitative serum immunoglobulins | gMG at week 26: IgG below LLN in 29% against 8% placebo; IgM below LLN in 16% against 4%. Consider discontinuing with serious opportunistic or recurrent infections, or hypogammaglobulinemia needing IVIG | FDA label |
| At-risk patients | HBV reactivation | Fulminant hepatitis, hepatic failure and death reported with B-cell depleting therapies; reactivation seen in a patient on Uplizna in the gMG trial and postmarketing | FDA label |
| Ongoing | PML symptoms or MRI findings | Withhold at the first sign and evaluate. No confirmed cases in trials; 1 death after new lesions with PML in the differential | FDA label |
| 26-week randomized period | Neutrophils and lymphocytes | gMG: neutrophils 0.5 to 1.0 x 10^9/L in 1% against 0% placebo; lymphocytes below the limit of normal in 35% against 31% | FDA label |
| B-cell depletion | CD20+ B-cell counts | gMG: below LLN by week 4 in 99% or more; remained below LLN in 96% or more of AChR positive patients for 52 weeks | FDA label |
Uplizna drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Immunosuppressants, including systemic corticosteroids | May increase infection risk; consider additive immune effects. Study 3 patients entered on a stable corticosteroid, a specified non-steroidal immunosuppressant or both | FDA label |
| Vaccines | All immunizations at least 4 weeks before initiation; live or live-attenuated vaccines not recommended during treatment or until B-cell repletion | FDA label |
| Infants exposed in utero | No live or live-attenuated vaccines until infant B-cell recovery is confirmed; non-live vaccines may be given, consider specialist input on response | FDA label |
| Pregnancy | Fetal B-cell depletion and lasting immune effects in mice; contraception during treatment and 6 months after the last dose. Pregnancy registry 1 (303) 724-4644 | FDA label |
| Lactation | No human data; human IgG is excreted in milk, effect on infant B cells unknown | FDA label |
| Contraindicated | Prior life-threatening infusion reaction to Uplizna, active hepatitis B, active or untreated latent tuberculosis | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe FEP policy below asks for more than the label does. It wants a positive AChR or MuSK antibody test, an MGFA class of II to IV and a documented baseline MG-ADL or QMG score. The neurologist's records usually answer what the plan is asking for.
- The plan wants another medicine tried firstThe FEP policy asks that one listed medicine did not work well enough, was not tolerated or cannot be used. Its list is an acetylcholinesterase inhibitor, azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, methotrexate or cyclophosphamide. Your neurologist documents which one applies.
- Screening results are missingHepatitis B, tuberculosis and antibody level results are required before the first dose. Amgen says your liaison can help with steps such as completing required labs and checking what the prior authorization still needs.
- The plan says no after reviewAmgen describes 2 next steps. Your doctor can ask for a medical exception with extra paperwork, or you and the office can appeal. The Amgen By Your Side team can explain both.
- A copay you cannot payCommercial insurance: the Amgen Commercial Co-Pay Program, as little as $0 for Uplizna and infusion costs. Medicare, Medicaid, VA, TRICARE and other government coverage are excluded. Our help paying page lists charity funds that may cover what remains.
- You live in Massachusetts or Rhode IslandAmgen's co-pay terms say residents of these 2 states are not eligible for administration support. That is the part of the program that covers the cost of giving the infusion.
- Medicare, Medicaid or no insuranceThe co-pay program does not apply. Amgen lists independent funds such as The Assistance Fund, Good Days, the PAN Foundation and NORD. Each sets its own rules, and Amgen does not run them.
- The renewal after a yearThe FEP policy renews for 12 months at a time, with up to 6 vials. For myasthenia gravis, it asks for a drop of at least 2 points in the MG-ADL or QMG score from baseline.
Amgen By Your Side
- A dedicated Patient Access Liaison who explains insurance, costs and appointments, and helps find an infusion center
- A benefits investigation after you sign a HIPAA release: what your plan covers, your likely costs and whether a prior authorization is needed Amgen insurance page
- The Amgen Commercial Co-Pay Program, as little as $0 out of pocket for Uplizna and infusion costs for eligible commercial insurance Amgen financial support
- Eligibility criteria and program maximums apply to the co-pay program; Amgen's pages give no dollar figure for the maximum Uplizna site
- Co-pay help is not open to Medicare, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE or other government coverage, under the program's terms Amgen financial support
- Residents of Massachusetts or Rhode Island are not eligible for the infusion administration part of the co-pay help Amgen financial support
- A list of independent charity funds: The Assistance Fund, Good Days, the PAN Foundation and NORD Amgen financial support
Questions prescribers' offices ask about Uplizna
What is the Uplizna dose for generalized myasthenia gravis?
The September 2026 label gives 300mg IV on day 1, 300mg IV 2 weeks later, then 300mg IV every 6 months counted from the first infusion. Dilute all 3 100mg/10mL vials (30mL) in 250mL 0.9% sodium chloride. Infuse by pump through a 0.2 or 0.22 micron in-line filter at 42, 125, then 333mL/hour, about 90 minutes.
Which gMG patients does the Uplizna indication cover?
Adults who are anti-AChR or anti-MuSK antibody positive, per the September 2026 label; the indication was added in December 2025. Study 3 randomized 238 patients, 190 AChR positive and 48 MuSK positive, MGFA class II to IV, on stable corticosteroid and/or non-steroidal immunosuppressive therapy. MG-ADL change at week 26 was -4.2 against -2.2 on placebo (difference -1.9, 95% CI -2.9 to -1.0). QMG change was -4.8 against -2.3 (difference -2.5, 95% CI -3.8 to -1.2).
What screening is required before the first Uplizna dose?
Three assessments, per the September 2026 label: HBV screening, quantitative serum immunoglobulins and TB evaluation with latent infection testing. Active HBV and active or untreated latent TB are contraindications. HBsAg-negative, HBcAb-positive patients or HBV carriers need hepatology input, and low immunoglobulins need immunology input. Give all immunizations per guidelines at least 4 weeks before initiation; live vaccines are not recommended during treatment.
What premedication and monitoring does Uplizna need?
Three premedications before every infusion and observation for at least 1 hour after it, per the September 2026 label. Give a corticosteroid IV 30 minutes prior (example methylprednisolone 80 to 125mg). Give an antihistamine (diphenhydramine 25 to 50mg) and an antipyretic (acetaminophen 500 to 650mg) orally 30 to 60 minutes prior. Infusion reactions occurred in 10.1% in the gMG randomized period. Check for active infection before every dose and monitor quantitative immunoglobulins during treatment and until B-cell repletion.
What do insurers ask for to approve Uplizna for gMG?
The FEP policy shown here took effect April 1, 2026 and cites the December 2025 label. It asks for age 18 or older, AChR or MuSK autoantibodies, MGFA class II to IV and a documented baseline MG-ADL or QMG score. It also asks for inadequate response, intolerance or contraindication to 1 listed agent, such as an acetylcholinesterase inhibitor or azathioprine. It approves 9 vials for 12 months, then 6 vials per 12 months with a 2-point or greater decrease in MG-ADL or QMG from baseline.
Free email alert
Get an email when the Uplizna label changes
One email the day the FDA revises the Uplizna prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Uplizna only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - UPLIZNA- inebilizumab injection (prescribing information revised September 2026, SPL version 11, and Medication Guide), Horizon Therapeutics USA (Amgen), via DailyMed, 2026-09-21.
- Cost, Savings, and Support | UPLIZNA® (inebilizumab-cdon), Amgen, 2026-11-13.
- What to Expect | UPLIZNA® (inebilizumab-cdon), Amgen, 2026-11-13.
- UPLIZNA® Insurance Coverage | Amgen By Your Side, Amgen, 2026-11-13.
- UPLIZNA® Financial Support Programs | Amgen By Your Side, Amgen, 2026-11-13.
- Frequently Asked Questions (FAQs) for UPLIZNA® | Amgen By Your Side, Amgen, 2026-11-13.
- Official Consumer Website | UPLIZNA® (inebilizumab-cdon), Amgen, 2026-11-13.
- Pharmacy Policy 5.99.018, Uplizna, Blue Cross Blue Shield Federal Employee Program, 2026-04-01.
- BLA 761142/S-004 supplement approval letter, generalized myasthenia gravis, FDA, 2025-12-11.
- BLA 761142/S-003 supplement approval letter, immunoglobulin G4-related disease, FDA, 2025-04-03.
- BLA 761142 approval letter, Uplizna (inebilizumab-cdon) for NMOSD, FDA, 2020-06-11.
A reference drawn from the September 21, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 13, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.